AGÕæÈ˹ٷ½

STOCK TITAN

CheqUp and WeightWatchers Announce Strategic Partnership to Support Growing Use of GLP-1 Medications in the UK

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
partnership
CheqUp and WeightWatchers (WW) have announced a strategic partnership to enhance GLP-1 medication-based weight loss services in the UK. The collaboration combines CheqUp's clinical support and health coaching with WeightWatchers' GLP-1 Companion Programme, targeting a market of 12 million UK residents qualifying for GLP-1 medications. The partnership offers CheqUp members free access to WeightWatchers' comprehensive support system, including nutritional guidance, tracking tools, and community support. Data from the U.S. shows that WeightWatchers members using obesity medications alongside their program lose 11% more weight than those using medication alone. In a study of 3,260 WeightWatchers Clinic patients, members achieved an average 21% body weight reduction at 12 months.
CheqUp e WeightWatchers (WW) hanno annunciato una partnership strategica per migliorare i servizi di perdita di peso basati su farmaci GLP-1 nel Regno Unito. La collaborazione unisce il supporto clinico e il coaching sanitario di CheqUp con il GLP-1 Companion Programme di WeightWatchers, rivolto a un mercato di 12 milioni di residenti nel Regno Unito idonei ai farmaci GLP-1. La partnership offre ai membri di CheqUp l'accesso gratuito al sistema di supporto completo di WeightWatchers, inclusi consigli nutrizionali, strumenti di monitoraggio e supporto comunitario. I dati dagli Stati Uniti mostrano che i membri di WeightWatchers che utilizzano farmaci per l'obesità insieme al loro programma perdono l'11% in più di peso rispetto a chi usa solo i farmaci. In uno studio su 3.260 pazienti della WeightWatchers Clinic, i membri hanno raggiunto una riduzione media del 21% del peso corporeo in 12 mesi.
CheqUp y WeightWatchers (WW) han anunciado una alianza estratégica para mejorar los servicios de pérdida de peso basados en medicamentos GLP-1 en el Reino Unido. La colaboración combina el apoyo clínico y el coaching de salud de CheqUp con el Programa Compañero GLP-1 de WeightWatchers, dirigido a un mercado de 12 millones de residentes en el Reino Unido que califican para medicamentos GLP-1. La asociación ofrece a los miembros de CheqUp acceso gratuito al sistema integral de apoyo de WeightWatchers, que incluye orientación nutricional, herramientas de seguimiento y apoyo comunitario. Los datos de EE.UU. muestran que los miembros de WeightWatchers que usan medicamentos contra la obesidad junto con su programa pierden un 11% más de peso que quienes usan solo la medicación. En un estudio con 3,260 pacientes de la WeightWatchers Clinic, los miembros lograron una reducción promedio del 21% del peso corporal en 12 meses.
°ä³ó±ð±ç±«±èê³� WeightWatchers (WW)ëŠ� ì˜êµ­ì—서 GLP-1 약물 기반 체중 ê°ëŸ‰ 서비스를 강화하기 위한 ì „ëžµì � 파트너십ì� 발표했습니다. ì´ë²ˆ í˜‘ë ¥ì€ CheqUpì� ìž„ìƒ ì§€ì›� ë°� ê±´ê°• 코칭ê³� WeightWatchersì� GLP-1 ë™ë°˜ìž� 프로그램ì� 결합하여 GLP-1 약물 대ìƒì´ ë˜ëŠ” ì˜êµ­ ë‚� 1,200ë§� ëª…ì˜ ì‹œìž¥ì� 목표ë¡� 합니ë‹�. ì� 파트너십ì� 통해 CheqUp 회ì›ë“¤ì€ ì˜ì–‘ ì§€ë�, ì¶”ì  ë„구, 커뮤니티 ì§€ì›ì„ í¬í•¨í•� WeightWatchersì� 종합 ì§€ì›� ì‹œìŠ¤í…œì„ ë¬´ë£Œë¡� ì´ìš©í•� ìˆ� 있습니다. 미국 ë°ì´í„°ì— 따르ë©�, WeightWatchers íšŒì› ì¤� 비만 약물ì� 프로그램ê³� 함께 사용하는 경우 약물ë§� 사용하는 사람보다 11% ë� ë§Žì€ ì²´ì¤‘ ê°ëŸ‰ì� 보였습니ë‹�. 3,260ëª…ì˜ WeightWatchers í´ë¦¬ë‹� 환ìžë¥� 대ìƒìœ¼ë¡� í•� 연구ì—서 회ì›ë“¤ì€ 12개월 ë™ì•ˆ í‰ê·  21%ì� 체중 ê°ì†Œë¥� 달성했습니다.
CheqUp et WeightWatchers (WW) ont annoncé un partenariat stratégique pour améliorer les services de perte de poids basés sur les médicaments GLP-1 au Royaume-Uni. Cette collaboration associe le soutien clinique et le coaching santé de CheqUp au programme compagnon GLP-1 de WeightWatchers, ciblant un marché de 12 millions de résidents britanniques éligibles aux médicaments GLP-1. Le partenariat offre aux membres de CheqUp un accès gratuit au système de soutien complet de WeightWatchers, incluant conseils nutritionnels, outils de suivi et soutien communautaire. Les données des États-Unis montrent que les membres de WeightWatchers utilisant des médicaments contre l'obésité en complément de leur programme perdent 11 % de poids en plus que ceux utilisant uniquement les médicaments. Dans une étude menée auprès de 3 260 patients de la clinique WeightWatchers, les membres ont obtenu une réduction moyenne de 21 % de leur poids corporel en 12 mois.
CheqUp und WeightWatchers (WW) haben eine strategische Partnerschaft angekündigt, um die auf GLP-1-Medikamenten basierenden Gewichtsverlustdienste im Vereinigten Königreich zu verbessern. Die Zusammenarbeit kombiniert CheqUps klinische Unterstützung und Gesundheitscoaching mit dem GLP-1-Begleitprogramm von WeightWatchers, das sich an einen Markt von 12 Millionen UK-Bewohnern richtet, die für GLP-1-Medikamente qualifiziert sind. Die Partnerschaft bietet CheqUp-Mitgliedern kostenlosen Zugang zum umfassenden Unterstützungssystem von WeightWatchers, einschließlich Ernährungsberatung, Tracking-Tools und Community-Support. Daten aus den USA zeigen, dass WeightWatchers-Mitglieder, die Adipositas-Medikamente zusammen mit ihrem Programm verwenden, 11 % mehr Gewicht verlieren als diejenigen, die nur Medikamente verwenden. In einer Studie mit 3.260 WeightWatchers-Klinikpatienten erreichten die Mitglieder innerhalb von 12 Monaten eine durchschnittliche Gewichtsreduktion von 21 %.
Positive
  • Partnership addresses a large market opportunity with 12 million UK residents qualifying for GLP-1 medications
  • Data shows 11% additional weight loss for members using both medication and WeightWatchers program
  • Study demonstrates strong efficacy with 21% average body weight reduction in 12 months
  • Service provided at no additional cost to CheqUp members
  • Potential for market expansion as UK Government considers wider GLP-1 medication rollout
Negative
  • None.

Insights

WeightWatchers' UK partnership with CheqUp expands their GLP-1 companion offering to a massive potential market, boosting growth opportunities.

This strategic partnership represents a significant market expansion opportunity for WeightWatchers in the rapidly growing GLP-1 medication space. The UK market presents enormous potential with 12 million people qualifying for GLP-1 prescriptions—a substantial addressable market. The UK government's consideration of wider GLP-1 medication rollout further validates the growth trajectory.

What makes this partnership particularly valuable is the demonstrated efficacy of WeightWatchers' companion program. Their U.S. data shows members using both GLP-1 medications and WeightWatchers' behavioral program lose 11% more weight than those using medication alone. Even more impressive, their study of 3,260 WeightWatchers Clinic patients demonstrated an average 21% body weight reduction at 12 months—exceptional real-world results that strengthen their value proposition.

This partnership follows WeightWatchers' strategic pivot toward embracing medication-assisted weight loss rather than competing against it. By positioning themselves as the behavioral companion to pharmaceutical interventions, they've created a complementary business model that leverages their core competency in behavioral change while adapting to market disruption.

For WeightWatchers, this partnership provides immediate access to CheqUp's established UK customer base without the capital expenditure of building their own prescription infrastructure. The model creates a seamless patient journey combining CheqUp's medication management and coaching with WeightWatchers' nutritional guidance and community support—addressing the full spectrum of patient needs without either company duplicating services.

Partnership Provides CheqUp Members Access to WeightWatchers� Proven GLP-1 Companion Programme to Aid in Achieving Superior and Sustainable Results

CHIPPENHAM, England, May 22, 2025 (GLOBE NEWSWIRE) -- , one of the UK’s leading providers of GLP-1 based weight loss services, and , the global leader in science-backed weight management, have announced a partnership that will combine the offerings of both organizations to benefit patients seeking sustainable weight loss through GLP-1 medication and behavioural support.

This partnership delivers a seamless solution that combines:

  • CheqUp’s human-centric approach to supporting prescribed weight loss medication with dedicated clinical support and live, one-to-one health coaching, and
  • WeightWatchersâ€� industry-leading, science-backed GLP-1 Companion Programme, which provides tailored nutritional and behavioural lifestyle support for individuals on GLP-1 medications.

Together, these complementary offerings provide a more effective solution to weight management, helping members achieve better results than with medication alone.

With 12 million people in the UK qualifying for prescription GLP-1 medications, this partnership addresses the growing demand in the market by offering a holistic model of care to those currently on, or considering, GLP-1 medication. The UK Government is already examining the case for a wider rollout of GLP-1 medications, recognizing the significant potential of these medications to improve health and impact work productivity.

“We are delighted that WeightWatchers chose CheqUp to be its strategic partner when it comes to holistic healthcare in the GLP-1 category,� said James Hunt, Deputy CEO of CheqUp. “We are seeing exponential growth in the number of people who are choosing CheqUp to help them through what is a sometimes difficult but incredibly rewarding journey of weight loss. There is no doubt that the addition of WeightWatchers� breakthrough GLP-1 companion programme will add enormously to our patients� ability to achieve sustainable weight loss through its science-backed and proven programmes, together with their global community of like-minded individuals. We are proud that WeightWatchers has put their trust in our human-centric approach and access to the expertise of our clinicians and Health Coaches. This partnership offers the most attractive proposition in the market for those looking to benefit from the incredible potential of GLP-1 medications and behaviour change.�

“The data is clear—we see in the U.S., that our members on obesity medications, who also participate in our nutritional and behavioural lifestyle program, lose 11% more weight on average than those using the medication alone. When medication is part of the journey, it’s the combination with behavioural support that leads to more sustainable, superior results,� said Scott Honken, Chief Commercial Officer at WeightWatchers. “At WeightWatchers, we recognize the demand for GLP-1 medications in the UK is growing as more people seek effective weight management solutions. That's why we’re proud to partner with CheqUp to deliver our GLP-1 Companion Programme to meet this growing need. Our behavioural program provides a structured, science-backed and supportive approach for those using GLP-1 medications to manage their weight safely, effectively, and sustainably.�

CheqUp members will now receive the following tools and resources from WeightWatchers� GLP-1 Companion Programme:

  • Nutritional guidance from experts including access to GLP-1 “go-toâ€� food recommendations to guide decisions towards more nutrient-dense foods that minimise side effects and support healthy weight loss.
  • A simple tracking experience with three daily nutrition targets including protein, fruits and vegetables, and hydration.
  • Judgement-free support through access to WeightWatchersâ€� vibrant members-only social network groups, where members can connect, glean nutrition and activity insights, and receive invaluable emotional support from others on a similar GLP-1 journey.
  • A comprehensive progress overview to track weight loss, identify trends, and provide a roadmap for future success.

The offering is available, at no cost, for all CheqUp members who pursue their weight loss journey with GLP-1 medications.

For more than 60 years, WeightWatchers has been at the forefront of weight management, transforming lives through its holistic, science-backed model of care. By integrating personalized, accessible support for eligible members with proven behavioural tools—and fostering connection through a community of members that is millions strong—WeightWatchers delivers support to help members achieve and sustain their goals. In fact, in a study of 3,260 WeightWatchers Clinic patients in the U.S., members lost on average 21% of their body weight at 12 months—real-world results that demonstrate the strength of WeightWatchers� programs.

About CheqUp
CheqUp is a leading provider of medically supervised weight loss programmes, offering personalised treatment plans, clinical oversight, and one-on-one coaching. CheqUp empowers individuals to take charge of their health through accessible and evidence-based solutions.

About WW International, Inc.
WeightWatchers is the global leader in science-backed weight management, providing an accessible, holistic model of care through our #1 U.S. doctor-recommended Points® Program, clinical interventions including weight-loss medications (U.S. only), and community support. Since 1963, we have empowered our millions of members to build healthy habits to live longer lives. Our innovative, trusted spectrum of solutions provides members with the tools and resources they need to reach and sustain their goals wherever they are on their journey. To learn more visit or .



For media inquiries, please contact:
CheqUp:
[email protected]
020 8050 9928

WeightWatchers:
Marielena Santana
[email protected]

FAQ

What does the WeightWatchers (WW) partnership with CheqUp include?

The partnership includes CheqUp's clinical support and health coaching combined with WeightWatchers' GLP-1 Companion Programme, offering nutritional guidance, tracking tools, community support, and progress monitoring at no cost to CheqUp members.

How effective is WeightWatchers' program when combined with GLP-1 medications?

According to U.S. data, WeightWatchers members using obesity medications alongside the program lose 11% more weight than those using medication alone, with clinic patients losing an average of 21% body weight in 12 months.

How many people in the UK qualify for GLP-1 medications according to the partnership announcement?

According to the announcement, 12 million people in the UK qualify for prescription GLP-1 medications.

What specific tools does WeightWatchers (WW) provide to CheqUp members through the GLP-1 Companion Programme?

The program provides nutritional guidance, GLP-1 food recommendations, daily nutrition tracking for protein, fruits, vegetables, and hydration, access to members-only social network groups, and comprehensive progress tracking tools.
Ww Intl Inc

NASDAQ:WW

WW Rankings

WW Latest News

WW Latest SEC Filings

WW Stock Data

3.76B
90.59M
2.25%
0.13%
Personal Services
Services-personal Services
United States
NEW YORK